18 Apr, 2024 Managed Entry Agreements (MEAs) under scrutiny once more in Belgium By Jean-Christophe Top Joost Haans Marco de Morpurgo Lyndsey Hudson +1 more... Show less Impressive advancements in the pharma industry provide hope to patients affected by debilitating and life-threatening diseases and a...
24 Mar, 2023 Inspirational Women in Life Sciences Series - an interview with Lyndsey Hudson By Lyndsey Hudson Mary Foord-Weston In the second of our Cortex series on Inspirational Women in Life Sciences, we are proud to feature DLA Piper’s very own Dr Lyndsey...
21 Nov, 2022 Inspiring Women in the Life Sciences Industry: what we can learn from them By Lyndsey Hudson As someone who believes strongly in empowering women in the workplace and building a diverse and inclusive culture, I really enjoyed...
16 May, 2022 Innovation, strategy and collaboration aplenty at the LSX World Congress 2022 By Lyndsey Hudson It was really fantastic to attend the LSX World Congress 2022 in London on 10th and 11th May. So many excellent conversations to be had...
26 Jan, 2022 Initiative launched to accelerate EU clinical trials (ACT EU) By Lyndsey Hudson Accelerating Clinical Trials in the EU (ACT EU) was launched a few days ago, with the aim of transforming the way in which clinical...
10 Jan, 2022 AI-based clinical decision-making tools need better access to more representative data By Lyndsey Hudson The launch of Nightingale Open Science last month – a new hub of medical data sets that could train AI (Artificial Intelligence) systems...
06 Dec, 2021 The importance of regional innovation hubs in supporting the UK's Life Sciences Vision By Lyndsey Hudson Following on from my recent comments about the UK being a viable location to be a life sciences startup - with the right governmental...
23 Nov, 2021 Is the UK the right home for life sciences startups? By Lyndsey Hudson I saw this recent article highlighting the need for the UK to create a much more supportive and sustainable environment for life sciences...